Thomas Leblanc

Montreal

Podcast Host and Producer at Chosen Family

Articles

Prepared List of Questions to Ask Your Doctor About Cancer Diagnosis and Treatment

2 weeks ago | patientpower.info | Aaron Tallent |Thomas W. LeBlanc |Thomas Leblanc

Being diagnosed with cancer can be overwhelming, and you may find it challenging just to process the news, let alone know what questions to ask your doctor. To help you prepare to discuss your disease and next steps with your care team, here is a list of questions shared by one breast cancer survivor that may be useful for you to consider.
Exercise and Dexamethasone May Relieve Cancer Fatigue

2 weeks ago | patientpower.info | Hailey Hudson |Thomas W. LeBlanc |Thomas Leblanc

Many cancer patients experience severe fatigue because of the stress on their body from the disease burden and the intense treatments they’re going through. Unfortunately, there aren’t effective therapies available to help curb this fatigue and improve quality of life. The University of Texas MD Anderson Cancer Center recently released a pilot study looking at the combination of exercise and dexamethasone to help with cancer-related fatigue.
Future Perspectives on Menin Inhibitors in Acute Leukemias

2 months ago | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more

Opinion Video February 11, 2025 Author(s): , Panelists discuss preclinical findings on the potential role of menin inhibitors in relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL), the implications of p-MEF2C as a biomarker for reshaping the therapeutic landscape and integrating menin inhibitors such as revumenib into clinical practice, and what they anticipate learning from the upcoming presentation on menin inhibitor resistance, highlighting the role of MEN1 mutations in...
Emerging Combination Strategies and Preclinical Findings

2 months ago | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more

Opinion Video February 5, 2025 Author(s): , Panelists discuss the interim phase 1a results from KOMET-007 in newly diagnosed NPM1-mutated or KMT2A-rearranged AML, the potential role of ziftomenib combined with 7 plus 3 chemotherapy in standard induction therapy for high-risk acute monocytic leukemia (AML) patients with these mutations, preclinical findings on the combination of ziftomenib and selinexor in NPM1-mutant AML, and the mechanistic synergy between these therapies, exploring their...
Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS

2 months ago | targetedonc.com | Thomas W. LeBlanc |Thomas Leblanc

January 31, 2025By Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of early and accurate diagnosis, considering newer therapies like luspatercept, monitoring hemoglobin levels, and incorporating patient-reported outcomes to tailor individualized treatment plans for better outcomes.
MRD Testing and the Role of Revumenib in Treatment Response

2 months ago | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.
Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024

Jan 24, 2025 | targetedonc.com | Thomas W. LeBlanc |Thomas Leblanc

January 24, 2025By Thomas W. LeBlanc, MD, MA, discusses how treatment regimens for low-risk myelodysplastic syndromes (LR-MDS) significantly impact health-related quality of life (HRQOL), with data from the COMMANDS study (Oliva et al, ASH 2024, Abstract 3216) highlighting the correlation between HRQOL and clinical end points, and explore how incorporating HRQOL data into clinical decision-making can guide more patient-centered treatment choices in community settings.
Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

Jan 22, 2025 | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more

OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.
Adverse Event Management and Patient Safety With Revumenib

Jan 22, 2025 | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more

OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss the most commonly seen adverse effects (AEs) in menin inhibitor treatment, strategies for managing and mitigating these AEs to optimize outcomes, and how they compare across approved and pipeline menin inhibitors, along with best practices for clinicians to manage differentiation syndrome, a critical safety concern.
Considerations for Treatment Sequencing in LR-MDS

Jan 17, 2025 | targetedonc.com | Thomas W. LeBlanc |Thomas Leblanc

January 17, 2025By Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes (LR-MDS) include limited access to newer therapies, patient-specific factors, and treatment sequencing complexities, and explores strategies to address these barriers, such as improving health care access, optimizing patient selection, and enhancing treatment guidelines.